A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Trial Profile

A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Astodrimer (Primary)
  • Indications Bacterial infections; Bacterial vaginosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2012 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2012 This trial has reached 60% its targeted enrolment, according to a Starpharma media release.
    • 12 Apr 2012 New source identified and integrated, ClinicalTrials.gov record NCT01577238.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top